Merck v. Integra: § 271(e)(1) Safe Harbor

On June 13, 2005, the U.S. Supreme Court issued a unanimous decision in Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005), broadly construing the “safe harbor” exemption from patent infringement in 35 U.S.C. § 271(e)(1). The ruling, authored by Justice Scalia, is the leading Supreme Court authority on how far a researcher can go in using someone else’s patented compound or technology without committing infringement, as long as the work is reasonably related to developing information for the U.S. Food and Drug Administration. For university technology transfer offices (TTOs) and general counsel, it is the case most often cited when a faculty investigator asks whether using a third party’s patented compound, cell line, or research reagent in early-stage drug or device research exposes the institution to an infringement claim.

This guide explains what the Court actually held, the facts that produced it (research conducted at a private, nonprofit biomedical research institute, not a pharmaceutical company’s own labs), how the statutory safe harbor differs from the much narrower common-law experimental-use exemption that Madey v. Duke University left standing for universities, and what the decision does not resolve — specifically, whether patents on research tools themselves fall within its scope.

What 35 U.S.C. § 271(e)(1) says, and why Congress wrote it

Section 271(e)(1) was added by the Drug Price Competition and Patent Term Restoration Act of 1984 — commonly known as the Hatch-Waxman Act. It provides that it is not an act of infringement to make, use, offer to sell, or sell a patented invention “solely for uses reasonably related to the development and submission of information” under federal law regulating the manufacture, use, or sale of drugs or medical devices. Congress’s original purpose was narrow: allow a generic drug manufacturer to begin the testing needed for an Abbreviated New Drug Application (ANDA) before the brand-name patent expired, so a generic could launch immediately upon expiration rather than losing additional years to post-expiration testing. The provision is often called the “FDA exemption” or the “Hatch-Waxman safe harbor” for this reason.

The statutory language, however, is not limited to generic-drug ANDA testing. It refers broadly to “information” submitted “under a Federal law which regulates the manufacture, use, or sale of drugs” — and it was that breadth the Supreme Court was asked to interpret in Merck v. Integra.

The facts: research at a nonprofit institute, funded by a company, using another company’s patents

Integra Lifesciences held patents covering RGD peptides — short peptide sequences that bind to integrin receptors and can block angiogenesis, the growth of new blood vessels that solid tumors depend on. Research on RGD-integrin biology originating at the Scripps Research Institute, a private nonprofit biomedical research institute in La Jolla, California, had identified this mechanism as a promising target for anti-cancer and anti-angiogenic drug candidates. Merck KGaA (the German pharmaceutical company, unrelated to the separate U.S. company Merck & Co.) funded ongoing research at Scripps aimed at identifying and developing a drug candidate built around this mechanism.

Integra sued Merck KGaA, Scripps, and the Scripps researcher for patent infringement. A jury found infringement and rejected the safe-harbor defense; the Federal Circuit affirmed, reading § 271(e)(1) narrowly — holding it did not “globally embrace all experimental activity that at some point, however attenuated, may lead to an FDA approval process,” and treating the Scripps work as general biomedical research too far removed from an actual regulatory submission to qualify.

The Supreme Court’s holding: the safe harbor is broad, not limited to clinical-trial-stage testing

The Supreme Court reversed unanimously. It held that use of a patented compound in preclinical studies is protected under § 271(e)(1) as long as there is “a reasonable basis to believe that the compound tested could be the subject of an FDA submission” and the experiments will “produce the types of information relevant to an IND or NDA.” Congress, the Court reasoned, did not limit the exemption to studies that actually generate data included in an eventual FDA submission, nor to a particular stage of drug development — it exempted all uses of a patented invention that are reasonably related to the process of developing information for a submission under any federal law regulating drugs, devices, or biologics. That the research was funded by one company and conducted at an unaffiliated nonprofit institute, that no drug application was ever filed, and that the specific compounds tested never advanced past screening did not remove the work from the exemption.

The Court did draw a line. It stated that basic scientific research on a compound, conducted without any intent to develop a particular drug and without a reasonable belief the compound would produce the physiological effect the researcher was investigating, falls outside the safe harbor. The exemption protects regulatory-development-directed research; it does not convert § 271(e)(1) into a general research exemption for patented technology. The Court remanded the case for the Federal Circuit to apply this standard to the specific studies at issue, several of which turned out, on remand, to fall on the “basic research” side of that line and remained infringing. See Integra Lifesciences I, Ltd. v. Merck KGaA, 496 F.3d 1334 (Fed. Cir. 2007).

What the decision left open: patents on research tools

One question the Court explicitly did not need to decide is whether § 271(e)(1) covers patents on research tools — instruments, reagents, assays, or methods used to conduct research, as distinct from patents on a candidate drug substance itself. The RGD peptides in this case were themselves potential drug candidates under investigation, not merely tools used to study something else, so the Court did not have to reach the research-tool question. Federal Circuit and district court decisions since 2005 have continued to wrestle with where that line falls, and commentators generally advise treating the safe harbor’s protection for pure research-tool patents as unsettled rather than assumed. This is the single most important caveat for a TTO or university counsel applying Merck v. Integra to a specific fact pattern: a compound that is itself a candidate therapeutic being screened for FDA-relevant properties sits comfortably inside the holding; a patented reagent, antibody, or instrument used only to facilitate study of something else is in doctrinally murkier territory.

How this differs from the common-law research exemption universities actually have (Madey v. Duke)

Universities sometimes assume that nonprofit, educational research is categorically shielded from patent infringement claims. It is not. The narrow common-law “experimental use” exemption, most directly addressed for university research in Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002), excludes any use “in keeping with the alleged infringer’s legitimate business objectives” — and the Federal Circuit held that a research university’s own objectives (attracting faculty, students, grants, and prestige through research) count as business objectives for this purpose. In practice, the common-law exemption has been construed so narrowly since Madey that it offers almost no reliable protection for university research programs, regardless of nonprofit status.

The statutory § 271(e)(1) safe harbor is a different, and considerably broader, doctrine — but it is not a substitute for a general research exemption. It applies only where the work is reasonably related to developing information for submission under federal drug, biologic, or medical-device law. Research with no plausible connection to an eventual FDA submission gets no help from Merck v. Integra, no matter how basic-science-oriented or nonprofit the institution conducting it is. A university lab studying a third party’s patented compound as part of a program aimed, even at an early and exploratory stage, at an eventual FDA-regulated product has a real, Supreme-Court-endorsed defense; a lab using the same patented compound purely to answer a basic-science question unconnected to drug or device development does not.

Question	Common-law experimental-use exemption (post-Madey)	Statutory safe harbor, § 271(e)(1) (post-Merck v. Integra)
Source of the rule	Judge-made doctrine, narrowed sharply by the Federal Circuit	Statute enacted by Congress in 1984 (Hatch-Waxman)
What triggers protection	Use “solely for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry” — effectively unavailable to any institution with grant funding or commercialization goals	Use reasonably related to developing information for an eventual FDA submission (drug, biologic, or device)
Does nonprofit/educational status help?	No — Madey held a university’s research mission is a “legitimate business objective,” defeating the exemption	No direct relevance — the analysis turns on the regulatory purpose of the research, not who conducts it or their tax status
Reliability in practice	Very low; courts apply it almost never	Meaningful protection where the FDA-submission nexus can be shown, but does not clearly reach research-tool patents

Practical guidance for TTOs and university counsel

When a faculty investigator or a TTO licensing officer asks whether research involving a third party’s patented compound, reagent, or technology is protected, the analysis Merck v. Integra supports generally turns on:

Is there an FDA-regulated endpoint in view? Research aimed, even speculatively, at identifying or characterizing a drug, biologic, or device candidate has a plausible safe-harbor argument. Research with no connection to drug/device/biologic regulatory approval does not, regardless of scientific merit.
Is the patented material the subject of the study, or a tool used to study something else? The safe harbor’s application to the drug candidate itself is well established after Merck v. Integra; its application to a patented research tool used incidentally is not settled law, and should be flagged for case-specific legal review rather than assumed.
Document contemporaneous intent. Because the Court’s test asks whether there was “a reasonable basis to believe” the work could support an FDA submission, protocols, grant applications, and sponsored-research agreements that record the regulatory-development purpose of a study at the time it was designed are more useful evidence than a post hoc characterization offered after an infringement dispute arises.
Don’t rely on nonprofit or academic status alone. Neither Merck v. Integra nor Madey v. Duke gives universities a general research exemption from patent infringement. A sponsored-research agreement, material transfer agreement, or license covering the patented compound or tool remains the more reliable protection where one can be negotiated.
Treat research-tool patents as a distinct risk category. Where a project depends on a patented reagent, cell line, antibody, or instrument that is not itself a drug candidate under study, pursue a license or MTA rather than relying on § 271(e)(1), given the open question described above.

Frequently asked questions

What is the Merck KGaA v. Integra Lifesciences safe harbor?

It is the Supreme Court’s 2005 interpretation of 35 U.S.C. § 271(e)(1), holding that using a patented compound in preclinical research is exempt from patent infringement liability as long as there is a reasonable basis to believe the work could produce information relevant to an eventual FDA submission — even if no submission is ever made and the research is conducted by an institution other than the eventual drug sponsor.

Does the safe harbor protect university researchers who use a third party’s patented research tool?

Not clearly. The Supreme Court did not decide whether § 271(e)(1) covers patents on research tools (as opposed to patents on the drug candidate under investigation), because the compounds at issue in Merck v. Integra were themselves potential drug candidates. This remains an open, doctrinally unsettled question that university counsel should evaluate case by case rather than assume is resolved.

How is this different from the “experimental use” exemption universities sometimes cite?

The common-law experimental-use exemption addressed in Madey v. Duke University is a judge-made doctrine that the Federal Circuit has construed so narrowly it offers little practical protection to any institution, including universities, whose research furthers institutional objectives like grants and prestige. The § 271(e)(1) statutory safe harbor is a separate, broader doctrine, but it only applies where the research is reasonably related to an eventual FDA submission — it is not a general substitute for the common-law exemption.

What happened to the case after the Supreme Court’s ruling?

The Court reversed the Federal Circuit’s narrow reading and remanded. On remand, the Federal Circuit applied the Supreme Court’s “reasonable basis to believe” standard to the specific studies at issue and found that some of the accused research was basic science outside the safe harbor, while other studies qualified for protection. See Integra Lifesciences I, Ltd. v. Merck KGaA, 496 F.3d 1334 (Fed. Cir. 2007).

Does this case have anything to do with patentability of the compounds themselves?

No. Merck v. Integra is an infringement-exemption case — it determines when using someone else’s already-issued patent is nonetheless not infringement. It has no bearing on whether a compound or invention is patentable in the first place, which is governed by separate doctrines under 35 U.S.C. § 101 (subject-matter eligibility), § 103 (non-obviousness), and § 112 (enablement and written description).

Merck KGaA v. Integra Lifesciences (2005): The Research-Use Safe Harbor Under 35 U.S.C. § 271(e)(1)